Tekla Capital Management LLC decreased its position in shares of Mirati Therapeutics, Inc. (NASDAQ:MRTX – Get Rating) by 46.5% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 65,490 shares of the biotechnology company’s stock after selling 56,900 shares during the period. Tekla Capital Management LLC owned 0.11% […]
Mirati Therapeutics, Inc. (NASDAQ:MRTX – Get Rating)’s share price was down 6.9% during mid-day trading on Thursday . The stock traded as low as $43.13 and last traded at $43.27. Approximately 283,886 shares changed hands during trading, a decline of 74% from the average daily volume of 1,081,235 shares. The stock had previously closed at […]
Mirati Therapeutics (NASDAQ:MRTX – Get Rating)‘s stock had its “reiterates” rating reiterated by analysts at 22nd Century Group in a research report issued to clients and investors on Thursday, Benzinga reports. A number of other research analysts also recently issued reports on MRTX. Morgan Stanley cut their price target on Mirati Therapeutics from $60.00 to […]
Mirati Therapeutics (NASDAQ:MRTX – Get Rating)‘s stock had its “maintains” rating reissued by stock analysts at VNET Group in a research report issued on Thursday, Benzinga reports. A number of other research firms have also issued reports on MRTX. B. Riley increased their target price on shares of Mirati Therapeutics from $52.00 to $56.00 and […]
22nd Century Group reiterated their reiterates rating on shares of Mirati Therapeutics (NASDAQ:MRTX – Get Rating) in a report released on Thursday, Benzinga reports. Several other research firms also recently issued reports on MRTX. BMO Capital Markets reduced their price target on shares of Mirati Therapeutics from $59.00 to $50.00 and set a market perform […]